4basebio PLC - Heidelberg, Germany-based life sciences company - Pretax loss in the six months to June 30 widens to £3.9 million from £2.7 million a year prior. Revenue grows 57% to £238,000 from £152,000. Research and non-captialised development expenses however increase 56% to £1.6 million from £1.0 million. Administrative expenses increase 23% to £1.6 million from £1.3 million, as sales and marketing expenses increase to £248,000 from £97,000. Looking ahead, expects to secure new clients in the second half of 2023.

Current stock price: 599.00 pence, closed 1.8% lower on Thursday in London

12-month change: up 4.2%

Copyright 2023 Alliance News Ltd. All Rights Reserved.